Target ALS and Modality.AI have partnered to launch a direct-to-participant study using Modality.AI’s cutting-edge audiovisual software to monitor disease symptoms in ALS patients. The platform captures speech, facial biomarkers, cognitive tasks, and motor functions, enabling participants to complete self-directed assessments from home twice a month over 16-18 months.
This approach supports Target ALS’ mission to break down barriers to ALS research by increasing participant diversity and retention while reducing the need for in-clinic visits and cutting time and costs.
“We’re excited to collaborate with Target ALS on the first clinical study of Modality’s remote monitoring platform,” said Modality.AI CEO David Suendermann-Oeft. “Speech, video, and multimodal analysis could transform remote neurological assessments, leading to faster and more efficient clinical trials and drug discovery.”
Five international sites within the Target ALS Global Natural History Study will recruit 150 ALS participants and 50 healthy controls to use Modality.AI’s platform over the next three years. Study results will be shared globally via the Target ALS Data Engine.
For more details on the collaboration and participation, view the official release here.
